#None #Waltham, Massachusetts #KRAS G12D #Ranok Therapeutics #RNK08954

Ranok Therapeutics' Significant Breakthrough

In an exciting update in the oncology field, Ranok Therapeutics, a clinical-stage biotechnology firm, has shared promising interim results from its Phase 1 clinical trial concerning RNK08954, a selective KRAS G12D inhibitor. This investigational oral therapy aims to treat patients suffering from KRAS G12D-mutated metastatic non-small cell lung cancer (NSCLC). The findings were recently highlighted during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held on June 1, 2026.

Study Overview

The multicenter Phase 1 clinical study, registered under NCT06667544, involved a cohort of 47 heavily pre-treated patients diagnosed with solid tumors characterized by KRAS G12D mutations. The primary objective was to assess the safety, tolerability, pharmacokinetics, and clinical efficacy of RNK08954 at varying doses. Based on the comprehensive evaluation, a daily dose of 1200 mg has been established as the Recommended Phase 2 Dose (RP2D).

Results of the Trial

The results, particularly for patients with metastatic NSCLC, show impressive figures. An Objective Response Rate (ORR) of 42.9% was recorded across all administered doses, along with a remarkable Disease Control Rate (DCR) of 95.9%. Further analysis at the RP2D of 1200 mg revealed an ORR of 50% among patients who were previously untreated with taxanes, highlighting the enhanced anti-tumor efficacy of RNK08954. The clinical team observed that the preventative measure of allowing patients to undergo earlier treatments without traditional chemotherapy provides a strong rationale for further investigation.

Moreover, durable responses were indicated through longitudinal follow-up. In the pooled cohort characteristics evaluated at doses of 400–1000 mg, the median progression-free survival (PFS) was noted at 7.6 months. Overall, a substantial 83.3% of evaluable patients reached a vital biological marker, achieving at least a 50% variant allele frequency (VAF) clearance of the mutant KRAS G12D clone. Impressively, 44.4% experienced complete molecular clearance of the driver mutation.

Expert Commentary

Professor Zhengbo Song, the lead investigator at Zhejiang Cancer Hospital, emphasizes the breakthrough nature of these results. He stated that the high response rate in taxane-naïve patients underlines the promising potential of RNK08954 in transforming treatment paradigms, particularly for advanced KRAS G12D-mutated NSCLC patients who previously had limited options.

Additionally, Iman El-Hariry, Chief Medical Officer of Ranok Therapeutics, reiterated the drug's competitive edge in the existing treatment landscape. The exhibited clinical benefits and tolerability suggest that RNK08954 will play a vital role in primary treatment lines, offering patients earlier therapeutic access.

Corporate Milestone and Future Plans

This significant update marks a crucial milestone for Ranok Therapeutics. Chief Executive Officer Weiwen Ying remarked that the results from ASCO portrayed a well-tolerated oral profile for RNK08954, granting the company discretion in expedited clinical development opportunities. The company aims to systematically measure RNK08954's viability across broader NSCLC demographics while exploring strategic combination regimens. Furthermore, the success of this clinical evidence supports their ongoing work to treat various oncogenic drivers across multiple tumor types.

About RNK08954

RNK08954 is not just another oral medication; it represents a new hope for patients contending with KRAS G12D mutations. The focus on an oral regimen underscores the unique pharmacokinetics, designed for effective and sustained target inhibition. This targeted therapy is poised for trial in combination with other treatments for diverse malignancies, including pancreatic ductal adenocarcinoma (PDAC) and other solid tumors.

In conclusion, the interim results provided by Ranok Therapeutics herald a new era of tailored treatment options for patients with KRAS G12D mutations, pairing innovation with improved healthcare outcomes.